Soligenix Reports Extended Positive Phase 2a Results for SGX302 Psoriasis Treatment

Soligenix reported extended top line results from its Phase 2a clinical trial of SGX302 in patients with mild-to-moderate psoriasis, with the investigational therapy demonstrating continued tolerability and clinical improvements using an optimized gel formulation. The company announced that SGX302 was well tolerated by all patients in cohort 3, with no drug-related adverse events identified during the treatment period, building on previous positive safety data from earlier cohorts. This extension phase enrolled an additional four patients treated with an improved topical gel formulation designed to enhance both dispensation and skin application, addressing practical aspects of treatment administration that can impact patient adherence and experience.

The Phase 2a trial has progressed into an extension cohort that maintained the same treatment duration as prior phases, with SGX302 gel applied to psoriasis lesions twice weekly over an 18-week period. SGX302 utilizes visible light-activated synthetic hypericin, representing a first-in-class photodynamic therapy mechanism that distinguishes it from conventional psoriasis treatments. This approach offers a noncarcinogenic alternative to existing photodynamic therapies, addressing significant safety concerns that have limited broader adoption of light-based treatments for chronic skin conditions. The updated findings underscore the potential of SGX302 as a novel therapeutic option for psoriasis patients, particularly those seeking alternatives to current systemic treatments or traditional phototherapy approaches that may carry long-term risks.

The clinical improvements observed with the optimized formulation suggest that formulation refinements can enhance both the practical administration and potentially the efficacy of photodynamic therapies. As a late-stage biopharmaceutical company focused on developing products for rare diseases with unmet medical needs, Soligenix's progress with SGX302 represents an important step toward addressing treatment gaps in dermatological conditions. The continued positive safety profile across multiple patient cohorts provides encouraging data for potential future development phases, though additional studies will be necessary to fully establish efficacy and long-term safety. The latest news and updates relating to Soligenix are available in the company's newsroom at https://ibn.fm/SNGX, while more information about the specialized communications platform covering this development can be found at https://www.BioMedWire.com.

These extended results come at a time when the psoriasis treatment landscape continues to evolve, with patients and clinicians seeking therapies that balance efficacy with favorable safety profiles and convenient administration. The photodynamic mechanism of SGX302, combined with its noncarcinogenic properties, positions it uniquely within the spectrum of available and emerging psoriasis treatments. The optimization of the gel formulation addresses practical considerations that often influence real-world treatment success, moving beyond pure efficacy metrics to encompass patient-centered design elements. As the development program advances, these formulation improvements may help facilitate broader acceptance and utilization if the therapy progresses to later-stage trials and potential commercialization, offering psoriasis patients a new mechanism of action with distinct safety advantages over some existing treatment options.